Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease

Doni, Elisa; Carli, Giuseppe; Rocco, Alice Di; Sassone, Marianna; Gandolfi, Sara; Patti, Caterina; Falisi, Erika; Salemi, Claudia; Visco, Carlo

doi:10.1002/hon.2241

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In literature, only the association between MCL, AIHA, and ITP are counted: it was observed that in the context of MCL, AIHA could develop more frequently in patients with indolent leukemic non-nodal disease, and suggested that this disease presentation could share some biological and pathogenic features with classical CLL, favoring the occurrence of hemolysis. Surprisingly, it was noted that concomitant AIHA in MCL is associated with early lymphoma progression, which is correlated with poor outcome [31]. However, the small number of cases reported does not allow us to reach any definite conclusion.…”

Section: Mantle Cell Lymphoma and Autoimmunitymentioning

confidence: 84%

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

Masciopinto

Dell’Olio

Robertis

et al. 2020

JCM

View full text Add to dashboard Cite

The connection between autoimmune disease (AID) and lymphoproliferative disorders is a complex bidirectional relationship that has long been a focus of attention by researchers and physicians. Although advances in pathobiology knowledge have ascertained an AID role in the development of lymphoproliferative diseases developing, results about AID influence on the prognosis of lymphoma are discordant. In this review, we collect the most relevant literature debating a direct or indirect link between immune-mediated diseases and lymphoma prognosis. We also consider the molecular, genetic, and microenvironmental factors involved in the pathobiology of these diseases in order to gain a deeper understanding of the nature of this link.

show abstract

Section: Mantle Cell Lymphoma and Autoimmunitymentioning

confidence: 84%

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

Masciopinto

Dell’Olio

Robertis

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…However, our sample size for lymphomas was small and also our patients present at late stage of the disease which is a risk factor of developing AIHA in hematological malignancy as explained by Ji Cheng et al [15]. The same as others wherever these conditions develop AIHA, the prognosis is poor but our study did not assess the survival rate as it was cross sectional study [16,17].…”

Section: Frequency Of Iha Among Different Types Of B Cell Neoplasmsmentioning

confidence: 87%

Untitled

2022

SCRI

View full text Add to dashboard Cite

Background: Hematological malignancies of the lymphoid lineage such as multiple myeloma, lymphomas and lymphoid leukemia are a burden to the world especially in Tanzania; anaemia is one of the presenting symptoms of these conditions and is found in almost 100% of the patients at diagnosis. Of particular importance Immune Hemolytic Anemia (IHA) which has a poor response to treatment and subsequently poor prognosis when it is associated with lymphoid malignancies. The aim of this study is to determine the magnitude of immune hemolytic anemia in lymphoid malignancies in Tanzania Methods: This was a cross sectional study that recruited 86 patients with lymphoid malignancies attending both Ocean Road Cancer Institute (ORCI) and Muhimbili National Hospital (MNH). The clinical features were captured using a well-structured questionnaire. Laboratory results for Full Blood Count (FBC), reticulocytes count, total, indirect and direct bilirubin and Lactate Dehydrogenase (LDH) were retrieved from the laboratory reporting system. Additionally, a blood sample for the Direct Antiglobulin Test (DAT) was taken from all participants. This test was performed at the Central Pathology Laboratory (CPL) of MNH. Data analysis was performed using Statistical Package for the Social Sciences (SPSS 20.0) and Microsoft excel 2010. Data analysis was performed using South Texas Art Therapy Association (STATA 15.0).Results: IHA, indicated by a positive DAT, was found in 10% of patients with lymphoid malignancies. Analysis of DAT among patients never exposed to chemotherapy showed a prevalence of 22%. Among 9 IHA cases, 2 were CLL (Chronic Lymphoid Leukaemia), 2 were MM (Multiple Myeloma), 3 was NHL (Non-Hodgkin Lymphoma), 1 was HL (Hodgkin Lymphoma) and 1 SLL (Small Lymphocytic Lymphoma). All 9 cases had decompensated hemolytic anemia. Conclusion:IHA is a real complication of chronic lymphoid malignancies and DAT should be included in tests done during the course of management.

show abstract

“…with an estimated incidence of 1% [8]. Drug-induced immune hemolytic anemia can be classified into an autoimmune type, a drug adsorption type, and a neoantigen type [9].…”

Section: Discussionmentioning

confidence: 99%

Drug-Induced Hemolytic Crisis During Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma: A Rare Hematologic Adverse Reaction

Xiao¹,

He²,

Wang³

et al. 2019

APT

View full text Add to dashboard Cite

With the increasing development of novel targeted agents, several subtypes of lymphoma are entering the chemotherapy-free era. The combination of Bruton's tyrosine kinase inhibitor ibrutinib and the BCL-2 inhibitor venetoclax has been proven to be highly effective in the treatment of relapsed/refractory mantle cell lymphoma (MCL). The most common adverse effects of this combined therapy are gastrointestinal, such as diarrhea, nausea or vomiting, and gastroesophageal reflux. However, hemolysis is a rare event. In this paper, we report a case of a 50-year-old MCL patient who experienced a hemolytic crisis during treatment with ibrutinib and venetoclax. The case demonstrates a rare but potentially lethal adverse event and emphasizes the need for suspicion of such an adverse reaction during this combination therapy.

show abstract

Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease

Cited by 5 publications

References 9 publications

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

Untitled

Drug-Induced Hemolytic Crisis During Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma: A Rare Hematologic Adverse Reaction

Contact Info

Product

Resources

About